AR111840A1 - Polipéptidos que antagonizan la señalización wnt en células tumorales - Google Patents
Polipéptidos que antagonizan la señalización wnt en células tumoralesInfo
- Publication number
- AR111840A1 AR111840A1 ARP180101427A ARP180101427A AR111840A1 AR 111840 A1 AR111840 A1 AR 111840A1 AR P180101427 A ARP180101427 A AR P180101427A AR P180101427 A ARP180101427 A AR P180101427A AR 111840 A1 AR111840 A1 AR 111840A1
- Authority
- AR
- Argentina
- Prior art keywords
- polypeptides
- wnt signaling
- tumor cells
- methods
- antagonize wnt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17173782 | 2017-05-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR111840A1 true AR111840A1 (es) | 2019-08-21 |
Family
ID=59021278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180101427A AR111840A1 (es) | 2017-05-31 | 2018-05-30 | Polipéptidos que antagonizan la señalización wnt en células tumorales |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US11033636B2 (enExample) |
| EP (1) | EP3630816B1 (enExample) |
| JP (1) | JP7216024B2 (enExample) |
| KR (1) | KR102717656B1 (enExample) |
| CN (1) | CN110637030B (enExample) |
| AR (1) | AR111840A1 (enExample) |
| AU (1) | AU2018276409B2 (enExample) |
| BR (1) | BR112019022729A2 (enExample) |
| CA (1) | CA3060401A1 (enExample) |
| CL (1) | CL2019003419A1 (enExample) |
| CO (1) | CO2019012329A2 (enExample) |
| EA (1) | EA201992808A1 (enExample) |
| ES (1) | ES2979194T3 (enExample) |
| HU (1) | HUE067691T2 (enExample) |
| IL (1) | IL270854B2 (enExample) |
| MA (1) | MA48760A (enExample) |
| MX (1) | MX2019014331A (enExample) |
| MY (1) | MY200744A (enExample) |
| NZ (1) | NZ758031A (enExample) |
| PE (1) | PE20200610A1 (enExample) |
| PH (1) | PH12019502602A1 (enExample) |
| PL (1) | PL3630816T3 (enExample) |
| TW (1) | TWI887192B (enExample) |
| UA (1) | UA125761C2 (enExample) |
| WO (1) | WO2018220080A1 (enExample) |
| ZA (1) | ZA201906610B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11033636B2 (en) * | 2017-05-31 | 2021-06-15 | Boehringer Ingelheim International Gmbh | Polypeptides antagonizing Wnt signaling in tumor cells |
| WO2019032628A1 (en) | 2017-08-07 | 2019-02-14 | The Regents Of The University Of California | GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS |
| CN111699003B (zh) | 2017-12-19 | 2024-05-03 | 瑟罗泽恩奥普瑞汀公司 | 抗lrp5/6抗体和使用方法 |
| JP7418332B2 (ja) | 2017-12-19 | 2024-01-19 | スロゼン オペレーティング， インコーポレイテッド | 抗フリズルド抗体及び使用方法 |
| CN118271444A (zh) | 2017-12-19 | 2024-07-02 | 瑟罗泽恩奥普瑞汀公司 | Wnt替代分子和其用途 |
| WO2020080941A1 (en) * | 2018-10-16 | 2020-04-23 | Umc Utrecht Holding B.V. | Anti- low-density lipoprotein receptor-related protein 5/6 antibodies |
| AU2020221797A1 (en) * | 2019-02-11 | 2021-08-12 | Surrozen Operating, Inc. | Modulation of WNT signalling in ocular disorders |
| US11578129B2 (en) * | 2019-03-29 | 2023-02-14 | Boehringer Ingelheim International Gmbh | LRP5 and PD-1 antagonist anticancer combination therapy |
| US20230183336A1 (en) * | 2019-08-14 | 2023-06-15 | Modmab Therapeutics Inc. | Antibodies that bind to lrp5 proteins and methods of use |
| WO2023250402A2 (en) * | 2022-06-22 | 2023-12-28 | Antlera Therapeutics Inc. | Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof |
| KR102920873B1 (ko) * | 2021-07-13 | 2026-02-02 | 인제대학교 산학협력단 | NEURL 유전자, 이를 포함하는 발현벡터 또는 NEURL 단백질을 유효성분으로 포함하는 β-카테닌 과발현으로 인한 암질환 예방 또는 치료용 약학조성물 |
| CN117897408A (zh) * | 2021-08-10 | 2024-04-16 | 热生物制品有限公司 | 新型tim-4结合剂的生成和表征 |
| CN114702588B (zh) * | 2022-04-27 | 2022-11-22 | 博际生物医药科技(杭州)有限公司 | 抗Nectin-4抗体和双特异性抗体 |
| CN120424217B (zh) * | 2025-04-30 | 2026-03-06 | 立凌生物制药(苏州)有限公司 | 靶向b细胞抗原和t细胞抗原的多特异性抗体及其应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| JP4271735B2 (ja) | 1997-04-15 | 2009-06-03 | メルク アンド カンパニー，インコーポレイティド | 新規のｌｄｌ−レセプター |
| US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
| US6926898B2 (en) | 2000-04-12 | 2005-08-09 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP1395285A4 (en) | 2001-05-17 | 2005-06-01 | Genome Therapeutics Corp | REAGENTS AND METHODS FOR MODULATING DKK-MEDIATED INTERACTIONS |
| JP4303105B2 (ja) | 2001-06-28 | 2009-07-29 | ドマンティス リミテッド | 二重特異性リガンドとその利用 |
| WO2003059934A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CN1678634A (zh) * | 2002-06-28 | 2005-10-05 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
| EP1558645B1 (en) | 2002-11-08 | 2011-07-27 | Ablynx N.V. | Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation |
| US8461155B2 (en) | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
| WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
| AU2006249144B2 (en) | 2005-05-18 | 2011-11-17 | Ablynx Nv | Improved NanobodiesTM against Tumor Necrosis Factor-alpha |
| WO2007027509A2 (en) | 2005-08-31 | 2007-03-08 | Biogen Idec Ma Inc. | Evaluating and treating scleroderma |
| JP2010500876A (ja) | 2006-08-18 | 2010-01-14 | アブリンクス エン．ヴェー． | Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド |
| US20100113339A1 (en) | 2006-09-08 | 2010-05-06 | Ablynx N. V. | Serum albumin binding proteins with long half-lives |
| JP2010511397A (ja) | 2006-12-05 | 2010-04-15 | アブリンクス エン．ヴェー． | 血清タンパク質と結合可能なペプチド |
| US20110091462A1 (en) | 2008-03-05 | 2011-04-21 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making and uses thereof |
| CA2721202A1 (en) | 2008-04-17 | 2009-10-22 | Hilde Adi Pierrette Revets | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
| US8716243B2 (en) | 2008-05-28 | 2014-05-06 | St. Jude Childen's Research Hospital | Methods of effecting Wnt signaling through Dkk structural analysis |
| CA2777527C (en) | 2009-12-23 | 2020-06-23 | Esbatech, An Alcon Biomedical Research Unit Llc | Method for decreasing immunogenicity |
| EP2531523A1 (en) | 2010-02-05 | 2012-12-12 | Ablynx N.V. | Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same |
| PH12012501744A1 (en) | 2010-03-03 | 2021-08-09 | Boehringer Ingelheim Int | Biparatopic abeta binding polypeptides |
| KR101899835B1 (ko) * | 2010-03-24 | 2018-09-19 | 제넨테크, 인크. | 항-ｌｒｐ６ 항체 |
| SG185416A1 (en) * | 2010-05-06 | 2012-12-28 | Novartis Ag | Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies |
| MX2012012927A (es) | 2010-05-06 | 2013-05-01 | Novartis Ag | Composiciones y metodos de uso para anticuerpos multivalentes terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6). |
| CN103501799A (zh) * | 2011-01-28 | 2014-01-08 | 莱兰斯坦福初级大学评议会 | Wnt组合物及其使用方法 |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| US8790650B2 (en) | 2011-04-28 | 2014-07-29 | Vanderbilt University | Methods of using an antibody to inhibit WNT-mediated cardiac remodeling |
| CA3141978A1 (en) | 2011-06-23 | 2012-12-27 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| MY167125A (en) | 2011-08-17 | 2018-08-13 | Glaxo Group Ltd | Modified proteins and peptides |
| US8883735B2 (en) | 2011-11-04 | 2014-11-11 | Novartis Ag | Low density lipoprotein-related protein 6 (LRP6)-half life extender constructs |
| SG10201601747XA (en) * | 2012-01-18 | 2016-04-28 | Genentech Inc | Anti-LRP5 Antibodies And Methods Of Use |
| AU2016357460B2 (en) * | 2015-11-18 | 2023-07-27 | Ablynx Nv | Improved serum albumin binders |
| PT3383425T (pt) * | 2015-12-04 | 2020-10-07 | Boehringer Ingelheim Int | Polipéptidos biparatópicos que antagonizam a sinalização wnt em células tumorais |
| US11033636B2 (en) * | 2017-05-31 | 2021-06-15 | Boehringer Ingelheim International Gmbh | Polypeptides antagonizing Wnt signaling in tumor cells |
| US11578129B2 (en) * | 2019-03-29 | 2023-02-14 | Boehringer Ingelheim International Gmbh | LRP5 and PD-1 antagonist anticancer combination therapy |
-
2018
- 2018-05-30 US US15/992,345 patent/US11033636B2/en active Active
- 2018-05-30 MX MX2019014331A patent/MX2019014331A/es unknown
- 2018-05-30 NZ NZ758031A patent/NZ758031A/en unknown
- 2018-05-30 MA MA048760A patent/MA48760A/fr unknown
- 2018-05-30 HU HUE18729376A patent/HUE067691T2/hu unknown
- 2018-05-30 PE PE2019002493A patent/PE20200610A1/es unknown
- 2018-05-30 EA EA201992808A patent/EA201992808A1/ru unknown
- 2018-05-30 AR ARP180101427A patent/AR111840A1/es unknown
- 2018-05-30 UA UAA201911920A patent/UA125761C2/uk unknown
- 2018-05-30 EP EP18729376.6A patent/EP3630816B1/en active Active
- 2018-05-30 CN CN201880033136.9A patent/CN110637030B/zh active Active
- 2018-05-30 JP JP2019565865A patent/JP7216024B2/ja active Active
- 2018-05-30 PL PL18729376.6T patent/PL3630816T3/pl unknown
- 2018-05-30 BR BR112019022729A patent/BR112019022729A2/pt unknown
- 2018-05-30 KR KR1020197033590A patent/KR102717656B1/ko active Active
- 2018-05-30 CA CA3060401A patent/CA3060401A1/en active Pending
- 2018-05-30 AU AU2018276409A patent/AU2018276409B2/en active Active
- 2018-05-30 TW TW107118382A patent/TWI887192B/zh active
- 2018-05-30 WO PCT/EP2018/064295 patent/WO2018220080A1/en not_active Ceased
- 2018-05-30 ES ES18729376T patent/ES2979194T3/es active Active
- 2018-05-30 MY MYPI2019006657A patent/MY200744A/en unknown
-
2019
- 2019-10-08 ZA ZA2019/06610A patent/ZA201906610B/en unknown
- 2019-10-31 CO CONC2019/0012329A patent/CO2019012329A2/es unknown
- 2019-11-20 PH PH12019502602A patent/PH12019502602A1/en unknown
- 2019-11-24 IL IL270854A patent/IL270854B2/en unknown
- 2019-11-25 CL CL2019003419A patent/CL2019003419A1/es unknown
-
2021
- 2021-05-10 US US17/316,042 patent/US12285493B2/en active Active
-
2025
- 2025-03-20 US US19/085,495 patent/US20250345448A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019012329A2 (es) | Polipéptidos que antagonizan la señalización wnt en células tumorales | |
| CO2018005680A2 (es) | Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales | |
| MX2019009468A (es) | Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer. | |
| CY1123290T1 (el) | Ενωσεις και μεθοδοι χρησης | |
| CY1122227T1 (el) | Ρυθμιση δραστικοτητας συμπληρωματος | |
| CL2018003123A1 (es) | Terapia de combinación para el tratamiento del cáncer | |
| MX2023007841A (es) | Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer. | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| ECSP17062716A (es) | Heterociclos bicíclicos como inhibidores de fgfr4 | |
| CO2020001981A2 (es) | Proteínas que se unen a nkg2d, cd16 y flt3 | |
| MX373323B (es) | Procesos de siembra en serie y usos de los mismos. | |
| MX381046B (es) | Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas. | |
| BR112018003269A2 (pt) | conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização | |
| BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
| UY37018A (es) | Inhibidores bicíclicos de pad4 | |
| IL260930B (en) | Administration of engineered t cells for treatment of cancers in the central nervous system | |
| MX2018000778A (es) | Metodos para tratar trastornos mediados por hepcidinas. | |
| CL2018002810A1 (es) | Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada. | |
| MX373818B (es) | Composiciones de apilimod y métodos para usar las mismas. | |
| MX385138B (es) | Inmunomoduladores de aminoacilindazol para el tratamiento de enfermedades autoinmunes. | |
| UY37980A (es) | Compuestos novedosos para tratar enfermedades parasitarias | |
| IL259486A (en) | Agents for the treatment of diseases associated with undesired cell proliferation | |
| MX2016015163A (es) | Biomarcadores mit y metodos para su uso. | |
| EA201691887A1 (ru) | Лечение внутрипеченочных холестатических заболеваний | |
| MX2016009655A (es) | Metodos novedosos para el tratamiento del cancer. |